Acute myeloid leukemia in the elderly

Blood Reviews

Volumn 12, Issue 3, 1998, Pages 145-153

  Harousseau, J L ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CYTARABINE; GROWTH FACTOR; IDARUBICIN; INTERCALATING AGENT; PLACEBO;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; BRAIN TOXICITY; DRUG TOXICITY; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; MYELODYSPLASIA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0031663923     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(98)90012-1     Document Type: Article

References (39)

1. Hamblin TJ. Disappointments in treating acute leukemia in the elderly. N Engl J Med 1995; 332: 1712-1713.
2. Champlin RE, Gajewski JL, Golde DW Treatment of acute myelogenous leukemia in the elderly. Semin Oncol 1989; 16: 51-56.
3. Johnson PRE, Liu Yin JA. Acute myeloid leukaemia in the elderly: biology and treatment. Br J Haematol 1993; 83: 1-6.
4. Mayer RJ, Davis RB, Shiffer CA, et al. Intensive post-remission in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896-903.
5. Stone RM, Mayer RJ. The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clinics N Amer 1993; 7: 65-79.
6. Hamblin T. The treatment of acute myeloid leukemia preceded by the myelodysplastic syndrome. Leuk Res 1992; 16: 101-108.
7. Brito-Babapulle F, Catovsky D, Galton DAG. Clinical and laboratory features of de novo acute myeloid leukemia with trilineage myelodysplasia. Br J Haematol 1987; 66: 445-470.
8. Goasguen JE, Matsuo T, Cox C. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Leukemia 1992; 6: 520-525.
9. Gahn B, Haase D, Unterhalt M. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia 1996; 10: 937-942.
10. Dastugue N, Payen C, Lafage PD, et al. Prognostic significance of karyotype in de novo acute myeloid leukemia. Leukemia 1995; 9: 1491-1498.
11. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 1997; 89: 3323-3329.
12. List AF. Role of multidrug resistance and its pharmacologic modulation in acute myeloid leukemia. Leukemia 1996; 10: 937-942.
13. Berman E, Heller G, Santorsa JA, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666-1674.
14. Wiernik PH, Banks PLC, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313-319.
15. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin or daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 1184-1194.
16. Reiffers J, Huguet F, Stoppa A, et al. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996; 10: 389-395.
17. Mandelli F, Petti MC, Ardia A, et al. A randomized clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non lymphocytic leukaemia. Eur J Cancer 1991; 27: 750, 755.
18. Liu Yin JA, Johnson PRE, Davies JM, Flanagan NG, Gorst DW, Lewis MJ. Mitozantrone and cytosine-arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1991; 79: 415-420.
19. Bow EJ, Jutherland JA, Kirpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: Remission-induction using a non-cytarabine containing regimen of mitoxantrone plus etoposide. J Clin Oncol 1996; 14: 1345-1352.
20. Rowe JM, Andersen J. Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. A study of the Eastern Cooperative Oncology Group. Blood 1995; 86: 457-462.
21. Stone RM, Berg DT, George SE, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995; 232: 1671-1677.
22. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995; 232: 1678-1683.
23. Godwin JE, Kopecky KJ, Head DR, et al. A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1995; 86 (suppl 1): 434a (abstract).
24. Witz F, Harousseau JL, Sadoun A, et al. GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia. Blood 1995; 86 (suppl 1): 512a (abstract).
25. Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase II randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 1997; 90: 2952-2961.
26. Lowenberg B, Zittoun R, Kerhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989; 7: 1268-1274.
27. Yates J, Glidewell O, Wiernik P, et al. Cytosine-arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982; 60: 654-662.
28. Kahn SB, Begg CB, Mazza JJ, et al. Full dose versus attenuated dose daunorubicin, cytosine arabinoside and 6-thioguanine in the treatment of acute non-lymphocytic leukemia in the elderly. J Clin Oncol 1984; 2: 865-870.
29. Cheson BD, Jasperse DM, Simon R. et al. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986; 4: 1857-1864.
30. Powell BL, Capizzi RL, Muss HB, et al. Low-dose Ara-C therapy for acute myeloid leukemia in elderly patients. Leukemia 1989; 3: 23-8.
31. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute non-lymphocytic leukemia in the elderly. J Clin Oncol 1990; 8: 272-279.
32. Bezwoda WR, Dansey RD. Idarubicin plus cytarabine versus doxorubicin plus cytarabine in induction therapy for acute non-lymphoid leukemia: a randomized trial. Leukemia and Lymphoma 1990; 1: 221-225.
33. Lowenthal RM, Chesterman PN, Griffiths JD, et al. Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients. Cancer Treat Rep 1987; 71: 1279-1281.
34. Keldsen N, Karle H, Hansen NE, et al. Oral idarubicin in elderly patients with acute myeloid leukemia (letter). Eur J Haematol 1990; 45: 60.
35. Pagano L. Sica S, Marra R. Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients. Haematologica 1991; 76: 517-518.
36. Harousseau JL, Rigal-Huguet F, Hurteloup P, Guy H, Milpied N, Pris J Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent. Eur J Haematol 1989; 42: 182-185.
37. Harousseau JL, Huguet F, Reiffers J, et al. Oral idarubicin and low dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients. Leuk Lymphom 1991; 15: 145-149.
38. Ruutu T, Almquist A, Hallman H, et al. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Leukemia 1994; 8: 11-15.
39. Schiller GJ. Postremission therapy of acute myeloid leukemia in older adults. Leukemia 1996; suppl 1: S18-S20.